Lupin launches Molnupiravir for the COVID-19 treatment in India

7 Jan 2022 , 09:32 AM

This drug has been given emergency use authorization by the Drug Controller General of India (DCGI) for treatment of adult patients with COVID-19, with SpO2 > 93%, and the ones who have a high risk of progression of the disease including hospitalization.

Internationally, Molnupiravir is an oral antiviral that has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the U.S Food and Drug Administration (FDA) for the treatment of mild-to-moderate cases of COVID-19 in adults.

Molnupiravir inhibits the replication of SARS-CoV-2, the causative agent of COVID-19. Pre-clinical and clinical data have shown Molnupiravir to be effective against the most common SARS-CoV-2 variants including gamma, delta, and mu variants. Molnupiravir should be initiated as soon as possible after a diagnosis of COVID-19 and within five days of onset of symptoms.

Clinical data points suggest that Molnupiravir may be a gamechanger for the most vulnerable and immunosuppressed patients. This would include factors such as obesity, older age (>60 years), diabetes, or heart disease.

Lupin is a transnational pharmaceutical company. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The company eported a consolidated net loss of Rs 2,094.87 crore in Q2 FY22 as against net profit of Rs 213.51 crore in Q2 FY21. On a consolidated basis, net sales rose 5.9% to Rs 4,003.42 crore in Q2 FY22 over Q2 FY21.

The scrip shed 0.43% to currently trade at Rs 919.50 on the BSE.

Powered by Capital Market – Live News